Drugs / HRS-1301
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07608705 | Jun → Aug 2026 | hyperlipidemia | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07322016 | Jan → Aug 2026 | hyperlipidemia | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07097831 | Oct → Nov 2025 | hyperlipidemia | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06857253 | Mar → Aug 2025 | hyperlipidemia | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07229937 | Nov 2025 → Aug 2026 overdue | hyperlipidemia | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-1301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07097831 ↗ |
| Route | Oral | “HRS-1301 Dose 1，oral” NCT07229937 ↗ |